IONS

Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner, Biogen, shared compelling topline results from the Phase 2 CELIA study evaluating diranersen (IONIS-MAPTRx/BIIB080), an...

Tweedy Browne Co LLC lowered its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 15.0% during the fourth quarter, according to the company in its most recent filing with...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2026 virtual Annual Meeting of Stockholders followed by a general corporate update on Thursday, June 4...

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2027 earnings per share estimates for Ionis Pharmaceuticals in a report released on Thursday, April 30th. HC Wainwright analyst M. Kapoor anticipates that the company will post earni...

Kornitzer Capital Management Inc. KS bought a new stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) during the fourth quarter, according to its most recent filing with the Securities...

Wall Street Zen upgraded shares of Ionis Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research report on Saturday...

Vanguard Group Inc. decreased its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 0.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,440,459 shares of the company's...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: Bank of America Securities 2026 Health Care...

Royal Bank Of Canada upped their target price on shares of Ionis Pharmaceuticals from $95.00 to $100.00 and gave the company an "outperform" rating in a report on Thursday...